NASDAQ:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free LOGC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.07▼$2.0750-Day Range$2.04▼$2.0752-Week Range$0.26▼$3.77VolumeN/AAverage Volume652,526 shsMarket Capitalization$68.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LogicBio Therapeutics alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About LogicBio Therapeutics Stock (NASDAQ:LOGC)LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now LOGC Stock News HeadlinesSeptember 24, 2023 | finance.yahoo.comLogicBio's IPO: What You Need To KnowMarch 31, 2023 | uk.finance.yahoo.comRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports LtdMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.November 16, 2022 | finance.yahoo.comAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsNovember 14, 2022 | finanznachrichten.deLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 14, 2022 | finance.yahoo.comLogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 7, 2022 | benzinga.comShort Volatility Alert: LogicBio Therapeutics, Inc.October 17, 2022 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTXMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.October 4, 2022 | benzinga.comINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCOctober 3, 2022 | msn.comLooking Into LogicBio Therapeutics's Recent Short InterestOctober 3, 2022 | marketwatch.comLogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGCOctober 3, 2022 | bizjournals.comAstraZeneca acquires local startup at 660% premiumOctober 3, 2022 | finance.yahoo.comLogicBio's stock skyrockets after buyout bid for a 667% premiumOctober 3, 2022 | msn.comAstraZeneca pays 660% premium for gene therapy firm LogicBioOctober 3, 2022 | nasdaq.comLogicBio To Be Bought By Alexion, AstraZeneca Rare DiseaseOctober 3, 2022 | marketwatch.comAstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGCOctober 3, 2022 | msn.comWhy LogicBio Therapeutics Stock Is Soaring TodayOctober 3, 2022 | finance.yahoo.comAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic MedicineSeptember 21, 2022 | finance.yahoo.comLogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONESeptember 1, 2022 | reuters.comLogicBio Therapeutics IncAugust 18, 2022 | finance.yahoo.comEarnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their EstimatesAugust 16, 2022 | benzinga.comRecap: LogicBio Therapeutics Q2 EarningsJuly 27, 2022 | finance.yahoo.comLogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the UpgradeJune 14, 2022 | morningstar.comLogicBio Therapeutics Inc - Stock Quote LOGCMay 17, 2022 | finance.yahoo.comLogicBio® Therapeutics to Present at H.C. Wainwright Global Investment ConferenceMay 16, 2022 | finance.yahoo.comLogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business UpdatesSee More Headlines Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LOGC CUSIPN/A CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,030,000.00 Net Margins-246.71% Pretax Margin-246.71% Return on Equity-115.29% Return on Assets-53.01% Debt Debt-to-Equity Ratio0.17 Current Ratio1.99 Quick Ratio2.26 Sales & Book Value Annual Sales$5.41 million Price / Sales12.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book4.31Miscellaneous Outstanding Shares32,963,000Free Float30,293,000Market Cap$68.23 million OptionableNot Optionable Beta4.61 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Frederic Chereau M.B.A. (Age 55)Pres, CEO & Director Comp: $793.2kDr. Mark A. Kay M.D. (Age 64)Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $107.5kDr. Daniel J. Gruskin M.D. (Age 50)Chief Medical Officer Comp: $577.48kDr. Leszek Lisowski M.B.A.Ph.D., Co-Founder & Member of Scientific Advisory BoardDr. Adi Barzel Ph.D.Co-FounderMr. Joshua Blacher (Age 49)Interim CFO, Principal Financial Officer & Principal Accounting Officer Dr. Matthias Hebben Ph.D.Global VP & Head of Technology Devel.Dr. Mariana Nacht Ph.D. (Age 58)Chief Scientific Officer Ms. Andrea Paul J.D. (Age 41)Gen. Counsel & Corp. Sec. Ms. Grace LochheadVP & Head of HRMore ExecutivesKey CompetitorsIkena OncologyNASDAQ:IKNATurnstone BiologicsNASDAQ:TSBXElutiaNASDAQ:ELUTAligos TherapeuticsNASDAQ:ALGSAtara BiotherapeuticsNASDAQ:ATRAView All Competitors LOGC Stock Analysis - Frequently Asked Questions How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The company earned $2.12 million during the quarter, compared to the consensus estimate of $5.02 million. LogicBio Therapeutics had a negative net margin of 246.71% and a negative trailing twelve-month return on equity of 115.29%. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI). When did LogicBio Therapeutics IPO? (LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager. This page (NASDAQ:LOGC) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.